Research suggests the investigational drug asundexian could reduce the risk of recurrent ischemic stroke in those who have recently experienced a stroke or high risk transient ischemic attack (TIA). Unlike many existing anti-clotting treatments, it did not increase major or intracranial bleeding, addressing a major limitation of current therapies. The drug works by inhibiting Factor XIa, a clotting protein involved in harmful clot formation but …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.